Autres langues Huadong Medicine Co., Ltd

Actions

000963

CNE0000011S1

Cours en clôture Shenzhen S.E. Autres places de cotation 00:00:00 18/04/2024			Varia. 5j.	Varia. 1 janv.
31,52 ^CNY	+4,89 %		+6,96 %	-23,97 %

18/04	Les bénéfices de Huadong Medicine en 2023 augmentent de 14%	MT
17/04	Huadong Medicine Co. Ltd publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Huadong Medicine's 2023 Profit Jumps 14%	18/04
Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	17/04
El primer medicamento chino bioequivalente a Ozempic solicita su aprobación	03/04
China's first biosimilar Ozempic drug applies for approval	03/04
Huadong Medicine to Build 2 Billion Yuan Biopharma Innovation Center	09/02
Huadong Medicine to Invest 2 Billion Yuan in Biopharma Innovation Center	09/02
Huadong Medicine's 2023 Profit to Climb Up to 14.5%	01/02
Huadong Medicine Eyes Exclusive Marketing Rights for Cancer Drug Senaparib in China for 290 Million Yuan	21/12
Huadong Medicine's Unit Gains Chinese Drug Regulator's Nod to Trial Sirolimus Oral Solution	06/12
Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd., Hangzhou Gongshu State Investment Industry Development Co., Ltd.	15/11
Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm	14/11
Huadong Medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23
Huadong Medicine's Unit Gets Nod to Test Weight Management Drug; Shares Up 3%	15/09/23
MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzora Cream in Greater China	01/09/23
Huadong Medicine Enters Exclusive Licensing Agreement with Denmark’s MC2	01/09/23
CARsgen Announced 2023 Interim Results	23/08/23
Huadong Medicine’s H1 Profit Rises 7%; EPS, Revenue Miss Forecasts	16/08/23
Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	15/08/23
Huadong Medicine Buys Rights to US Skincare Drug For $100 Million	14/08/23
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia	11/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Huadong Medicine Co., Ltd

Actions

000963

CNE0000011S1

Autres langues

Filtres